Clinical Trial Detail

NCT ID NCT04165096
Title Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYNOTE-01C)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.

lung non-small cell carcinoma


MK-5890 + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.